Compare Biogen Inc (BIIB) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Teucrium Wheat Fund — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Teucrium Wheat Fund trades at $24.3. Which is the better fit depends on your goals.
| BIIB | WEAT | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.63 | $25.49 |
52-Week Low | $122.68 | $19.88 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
WEAT trades at $23.66, down 0.25% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows strong technical momentum with 17 buy signals versus 3 sell signals. Recent USDA production cuts and wheat price volatility of 15% monthly highlight commodity-driven price sensitivity. Key resistance sits at $24 with support at $23.
Outlook remains commodity-dependent with wheat futures driving performance. Investment opportunity exists through agricultural exposure, but risks include USDA forecast revisions and inflation impacts. The absence of traditional fundamental metrics requires reliance on commodity market analysis rather than corporate financials.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
